Institute submits NDA for PET to diagnose Parkinsonian syndromes

11/15/2012 | MedicalXpress.com

The Feinstein Institute for Medical Research said it has submitted a new-drug application to the FDA for the use of 18F-fluorodopa-PET in diagnosing Parkinsonian syndromes. The FDA earlier this year approved the institute's use of the scan as part of an expanded access investigational new drug program.

View Full Article in:

MedicalXpress.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI